Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
  Home Print this page Email this page Small font sizeDefault font sizeIncrease font size Users Online: 51  

 
   Table of Contents      
LETTER TO EDITOR
Year : 2016  |  Volume : 15  |  Issue : 1  |  Page : 73-74

Toxicity of therapy with Sm-153-EDTMP: To what extend can it be related to the tumor type?


1 Department of Nuclear Medicine, Dr. Władysław Biegański Regional Specialist Hospital, Grudziạdz; Department of Nuclear Medicine, Citomed, Toruń, Poland
2 Department of Nuclear Medicine, Citomed, Toruń, Poland
3 Department of Nuclear Medicine, Dr. Władysław Biegański Regional Specialist Hospital, Grudziạdz, Poland

Date of Web Publication18-Dec-2015

Correspondence Address:
Cyprian Swietaszczyk
Department of Nuclear Medicine, The Dr.Władysław Biegański Regional Specialist Hospital, Grudziạdz, Ludwik Rydygier Street 15-17, 86-300 Grudziạdz
Poland
Login to access the Email id


DOI: 10.4103/1450-1147.167603

PMID: 26912987

Rights and Permissions

How to cite this article:
Swietaszczyk C, Kobus-lachnio K, Pilecki SE. Toxicity of therapy with Sm-153-EDTMP: To what extend can it be related to the tumor type?. World J Nucl Med 2016;15:73-4

How to cite this URL:
Swietaszczyk C, Kobus-lachnio K, Pilecki SE. Toxicity of therapy with Sm-153-EDTMP: To what extend can it be related to the tumor type?. World J Nucl Med [serial online] 2016 [cited 2019 Dec 13];15:73-4. Available from: http://www.wjnm.org/text.asp?2016/15/1/73/167603

Dear Editor,

We have read the interesting case report of Keskin et al.[1] The authors suggest that a worsening of hemorrhagic pericardial effusion at the second day with fatal outcome 20 days later could be related to therapy with 37 MBq per 1 kg of body weight of samarium-153-ethylene diamine tetramethylene phosphonate (Sm-153-EDTMP) due to bone-metastasizing hepatocellular carcinoma.

Actually, a place of intensive bone remodeling caused by the tumor cells, not the tumor itself, is the address of the therapy. Hence the absorbed dose of radiation is roughly proportional to the accumulation of a bone-seeker [as technetium-99m methyl diphosphonate (Tc-99m-MDP)] on bone scan.[2],[3] It implies that a metastatic site that is very intensive in comparison to the surrounding (uninvolved) bone receives a very high dose, whereas the (marrow-bearing) normal bone is relatively spared [Figure 1] and [Figure 2]. Although the literature data seem scarce, the effect of such a therapy could sometimes even extend beyond merely palliation;[4],[5] in our own experience, there are some patients in whom a (transient) decrease of tumor marker level could be observed after therapy with Sm-153-EDTMP. In an opposite situation, where the uptake of a bone-seeker in metastatic sites is only slightly higher than in the normal bone, minimal or no therapeutic effect can be expected. This could be accompanied by significant marrow toxicity, which usually manifests after a time of between several days and a few weeks.
Figure 1: Osteoblastic metastatic foci in the right tibia and pelvis (smaller, masked by the enlarged bladder); after the bladder catheterization, therapy with Sm-153-EDTMP was performed

Click here to view
Figure 2: Multiple osteoblastic metastases visible 50 min after injection of Sm-153-EDTMP

Click here to view


From the Figure presented in the cited publication,[1] we infer that the patient had only a few bone metastatic foci, with only slightly enhanced accumulation of the radiotracer. Hence it can be expected that the ratio of the beneficial versus toxic effects of the therapy could be disadvantageous for the patient. The time of onset of the complications allows for the presumption, however, that their relation to the injection of Sm-153-EDTMP might be only loose, if there is any.

 
   References Top

1.
Keskin O, Soydal C, Deda X, Manti B, Tuzun A. Systemic Radiopharmaceutical Agents (Sm-153) may be Dangerous in Hepatacellular Carcinoma. World J Nucl Med 2015;14:51-2.  Back to cited text no. 1
[PUBMED]  Medknow Journal  
2.
Bianchi L, Baroli A, Marzoli L, Verusio C, Chiesa C, Pozzi L. Prospective dosimetry with 99mTc-MDP in metabolic radiotherapy of bone metastases with 153Sm-EDTMP. Eur J Nucl Med Mol Imaging 2009;36:122-9.  Back to cited text no. 2
    
3.
Pacilio M, Ventroni G, Basile C, Ialongo P, Becci D, Mango L. Improving the dose-myelotoxicity correlation in radiometabolic therapy of bone metastases with 153Sm-EDTMP. Eur J Nucl Med Mol Imaging 2014;41:238-52.  Back to cited text no. 3
[PUBMED]    
4.
Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fosså SD, et al.; ALSYMPCA Investigators. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013;369:213-23.  Back to cited text no. 4
    
5.
Nome R, Hernes E, Bogsrud TV, Bjøro T, Fosså SD. Changes in prostate-specific antigen, markers of bone metabolism and bone scans after treatment with radium-223. Scand J Urol 2015;49:211-7.  Back to cited text no. 5
    


    Figures

  [Figure 1], [Figure 2]



 

Top
 
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
    References
    Article Figures

 Article Access Statistics
    Viewed1216    
    Printed27    
    Emailed0    
    PDF Downloaded103    
    Comments [Add]    

Recommend this journal